The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | Adverse events associated with BTK inhibitor therapy in NHL
Nirav N. Shah, MD, Medical College of Wisconsin, Brookfield, WI, talks on adverse events associated with BTK inhibitor therapy. Ibrutinib, acalabrutinib and zanubrutinib are all BTK inhibitors used in the treatment of non-Hodgkin lymphoma. Dr Shah reports that cardiac toxicities are associated with BTK inhibitor therapy, in particular with ibrutinib, and comments on the need to develop drugs which minimise the risk of cardiac toxicities. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Nirav N. Shah, MD, has participated in consultancy work and advisory board with Lily Pharmaceuticals.
